Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the...
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is 'expensive' on EV/EBITDA, overvalued on P/F
Target Price
The average target price of CSTL is 49 and suggests 47% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell